查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1926850

BRAF抑制劑市場按適應症、藥物類型、治療領域、通路和最終用戶分類－2026-2032年全球預測

BRAF Inhibitors Market by Indication, Drug Type, Therapy Line, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 BRAF 抑制劑市場在 2025 年的價值為 15.5 億美元，在 2026 年成長至 16.6 億美元，複合年成長率為 7.94%，到 2032 年將達到 26.5 億美元。

關鍵市場統計數據
基準年 2025 15.5億美元
預計年份：2026年 16.6億美元
預測年份 2032 26.5億美元
複合年成長率 (%) 7.94%

本文全面介紹了分子診斷、治療順序和門診護理方面的趨勢如何重塑BRAF抑制劑在腫瘤學中的應用。

BRAF突變驅動型惡性腫瘤的治療格局正從以單一療法為中心的模式轉向需要精細臨床和商業性規劃的綜合性、多方面策略。分子診斷技術的進步使得BRAF V600突變的檢測在許多腫瘤治療路徑中成為常規操作。這種分子層面的可及性推動了對標靶小分子抑制劑及伴隨診斷的需求。因此，臨床開發、醫院處方集和專科診所的相關人員正在重新審視治療流程，以最佳化治療順序、聯合治療和患者選擇標準。

對正在從根本上改變BRAF抑制劑治療模式和市場動態的臨床、診斷和商業性轉折點進行詳細說明。

近年來，在更深入的分子分層和不斷發展的聯合治療方法方案的推動下，臨床醫生、監管機構和商業團隊對BRAF抑制劑的態度發生了變革性轉變。臨床實務越來越重視聯合標靶策略，以延緩或克服MAPK通路抗藥性，這促使處方醫師探索聯合治療，並將次世代定序整合到常規診斷流程中。這一趨勢也影響臨床試驗設計，使其轉向以生物標記為特徵的隊列和適應性通訊協定，旨在加速BRAF抑制劑在多種腫瘤類型中的適應症擴展。

對2025年關稅主導的貿易動態如何重塑BRAF抑制劑生態系統的供應鏈、籌資策略和商業協議進行全面評估

2025年關稅的實施和貿易政策調整正對BRAF抑制劑供應鏈的籌資策略、製造地地點和供應鏈韌性施加累積壓力。從國際原料藥的製造商面臨更高的到岸成本，因此正在加速供應商多元化、將關鍵流程遷回國內或加強垂直整合以降低風險。這些應對措施正在影響醫院和零售藥局（這些藥局負責腫瘤藥物處方集）的合約週期、庫存管理和前置作業時間。

詳細的細分分析清楚地展示了適應症、藥物類型、分銷管道、最終用戶、治療方案和口服給藥途徑等因素如何相互交織，從而驅動策略選擇。

細分市場分析揭示了在考慮適應症、藥物類型、分銷管道、終端用戶、治療方案和給藥途徑等因素時，臨床和商業性動態存在差異。例如，在大腸直腸癌（早期大腸直腸癌和轉移性大腸直腸癌）、肺癌（非小細胞肺癌和小細胞肺癌亞型）以及黑色素瘤（進行性和轉移性）等適應症類別中，臨床路徑的複雜程度差異顯著。轉移性大腸直腸癌的治療重點在於系統性治療的順序和合併治療策略，而早期大腸直腸癌的治療則更著重於根治性治療和輔助性治療的決策。

策略區域觀點：深入分析美洲、歐洲、中東和非洲以及亞太地區法規結構、支付方趨勢和診斷能力的差異，以及這些差異如何影響醫療服務的可及性和普及率。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的監管路徑、臨床應用和商業性准入有顯著影響。在美洲，某些司法管轄區的監管協調以及支付方的強大影響力促使相關人員優先考慮產生可靠的真實世界證據和衛生經濟學模型，以支持藥物上市。該地區的臨床試驗網路和學術機構通常率先採用者標籤擴展研究，從而加速了BRAF標靶治療的診斷應用和處方醫生採納。

在BRAF療法領域，決定永續商業性優勢的策略考量包括：投資組合策略、診斷合作、供應鏈選擇以及夥伴關係發展。

BRAF抑制劑研發和商業化領域的公司之間的競爭取決於產品組合的廣度、診斷夥伴關係以及供應鏈整合。擁有多元化腫瘤產品組合的公司可以利用跨產品組合的協同效應來支持市場進入，而專科公司則傾向於專注於擴展適應症、開展聯合用藥研究以及與關鍵高管進行有針對性的溝通，以推動藥物在特定適應症領域的應用。治療藥物研發公司與診斷服務提供者之間的夥伴關係是成功商業化的基石，它能夠確保及時檢測到突變，並使報銷文件與臨床決策通訊協定保持一致。

為製造商、支付方和醫療服務提供者提供以行動為導向的策略建議，以協調診斷、供應鏈彈性和商業性執行，從而實現持續的市場成功。

為了最大限度地發揮BRAF標靶治療的價值，產業領導者應優先考慮整合臨床開發和診斷、供應鏈韌性以及客製化商業性准入途徑的策略。投資於永續的診斷夥伴關係和就地檢驗途徑將加速識別合適的患者，並加強與支付方的溝通。同時，應設計真實世界證據項目，以解決對臨床醫生和醫保機構至關重要的療效比較和長期安全性問題。在營運方面，企業應進行供應鏈壓力測試，以應對關稅和貿易衝擊；考慮關鍵原料藥（API）的雙重採購；並在成本效益允許的情況下評估近岸外包和垂直整合，以保障供應的連續性。

應清楚解釋混合調查方法，該方法結合了專家訪談、監管檢驗和文獻檢驗，以確保研究結果的可靠性和可操作性。

本分析的調查方法結合了對腫瘤臨床醫生、藥屋主任和市場進入專家的定性調查，以及系統性的二手文獻回顧和公開的監管記錄。研究人員還採訪了關鍵產業領袖（KOL），檢驗臨床應用模式、實際治療順序以及對診斷工作流程的實際影響。此外，與醫院採購人員、專科藥房營運商和獨立診所經理的討論揭示了合約結構和庫存管理實踐方面的差異，並深入分析了供應鏈和分銷管道。

一份簡潔、全面且全面的分析報告，強調了整合臨床證據、診斷完整性和供應鏈韌性對於提升病患就醫便利性和商業性績效的重要性。

一項綜合分析表明，BRAF抑制劑領域的成功需要臨床差異化、診斷完整性和操作韌性的全面整合。臨床進展和合併治療策略需要同步產生證據，並制定切實可行的商業化計劃，以反映門診口服治療的實際情況。供應鏈和貿易政策趨勢，包括關稅帶來的成本壓力，凸顯了來源多元化和積極籌資策略的重要性，以維持醫療服務環境中的連續性並控制成本。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. BRAF抑制劑市場依適應症分類

  • 大腸直腸癌
    • 早期大腸直腸癌
    • MCRC
  • 肺癌
    • NSCLC
    • SCLC
  • 黑色素瘤
    • 進行性黑色素瘤
    • 轉移性黑色素瘤

9. BRAF抑制劑市場依藥物類型分類

  • Dabrafenib
  • Encorafenib
  • Vemurafenib

10. BRAF抑制劑市場依治療領域分類

  • 一線治療
  • 二級治療

第11章：BRAF抑制劑市場（依分銷管道分類）

  • 醫院藥房
    • 私立醫院藥房
    • 公立醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第12章：BRAF抑制劑市場（依最終用戶分類）

  • 醫院
    • 綜合醫院
    • 專科癌症中心
  • 專科診所
    • 醫院門診部
    • 獨立診所

13. BRAF抑制劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：BRAF抑制劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：各國BRAF抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國BRAF抑制劑市場

17. 中國BRAF抑制劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Asana BioSciences LLC
  • AstraZeneca
  • Bayer AG
  • BeiGene Ltd.
  • Black Diamond Therapeutics Inc
  • Bristol-Myers Squibb
  • C4 Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • Fore Biotherapeutics Inc
  • Jazz Pharmaceuticals Plc
  • Kinnate Biopharma Inc.
  • Nerviano Medical Sciences Srl
  • Novartis International AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
Product Code: MRR-4F7A6D4FF333

The BRAF Inhibitors Market was valued at USD 1.55 billion in 2025 and is projected to grow to USD 1.66 billion in 2026, with a CAGR of 7.94%, reaching USD 2.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.55 billion
Estimated Year [2026] USD 1.66 billion
Forecast Year [2032] USD 2.65 billion
CAGR (%) 7.94%

Comprehensive context on how molecular diagnostics, treatment sequencing, and outpatient care trends are reshaping BRAF inhibitor use across oncology settings

The treatment landscape for BRAF-driven malignancies has moved from monotherapy-centric approaches toward integrated, multidisciplinary strategies that require nuanced clinical and commercial planning. Advances in molecular diagnostics have made identification of BRAF V600 mutations routine in many oncology care pathways, and this molecular visibility has driven demand for targeted small-molecule inhibitors alongside companion diagnostics. As a result, stakeholders across clinical development, hospital formularies, and specialty clinics are reassessing treatment algorithms to optimize sequencing, combination regimens, and patient selection criteria.

This introductory overview frames the strategic implications for manufacturers, payers, and provider systems by highlighting the interplay between emerging clinical evidence, diagnostic adoption, and distribution dynamics. It underscores the importance of aligning supply chain capabilities and commercial channels with evolving prescriber preferences and outpatient care models. By setting this context, readers can better interpret subsequent sections that examine therapeutic shifts, tariff-driven supply impacts, segmentation-specific nuances, and regional differentials that shape access and uptake of oral BRAF inhibitors in contemporary oncology practice.

Detailed explanation of the clinical, diagnostic, and commercial inflection points that are fundamentally altering BRAF inhibitor treatment paradigms and market behavior

Recent years have delivered transformative shifts in how clinicians, regulators, and commercial teams approach BRAF inhibition, driven by deeper molecular stratification and evolving therapeutic combinations. Clinical practice has increasingly favored co-targeting strategies to delay or overcome MAPK pathway resistance, prompting prescribers to consider combination regimens and to integrate next-generation sequencing into routine diagnostic workflows. This trend has also influenced trial design toward biomarker-enriched cohorts and adaptive protocols that seek to accelerate label expansions across multiple tumor types.

Concurrently, the commercial landscape is adapting to the emergence of oral-only administration paradigms and decentralized care delivery, which places greater emphasis on outpatient support programs, adherence monitoring, and digital patient engagement. Distribution channels are shifting as hospital pharmacies negotiate tighter formulary criteria while online and retail pharmacies expand services to support oral oncology agents. These changes are accompanied by intensified collaboration between drug developers and diagnostic providers to ensure timely mutation detection and appropriate patient selection, thereby closing the loop between laboratory insights and therapeutic decision-making.

Comprehensive assessment of how tariff-driven trade shifts in 2025 are reshaping supply chains, procurement strategies, and commercial contracting across the BRAF inhibitor ecosystem

The imposition of tariffs and trade policy adjustments in 2025 exert cumulative pressure on procurement strategies, manufacturing footprints, and supply chain resilience for BRAF inhibitor supply chains. Manufacturers sourcing active pharmaceutical ingredients internationally have faced higher landed costs and have accelerated supplier diversification, reshoring of critical steps, or greater vertical integration to mitigate exposure. These operational responses have consequences across contracting cycles, inventory management, and lead times for hospital and retail pharmacies that maintain oncology formularies.

From a commercial perspective, payers and provider systems are reassessing cost-containment levers and reimbursement pathways as procurement economics shift. Larger integrated manufacturers with global supply networks are better positioned to absorb short-term tariff-related cost increases, while smaller specialty firms and contract manufacturers may seek to renegotiate distribution agreements or prioritize markets with more favorable trade terms. In parallel, distribution channel strategies have evolved with hospital pharmacies and specialty clinics emphasizing longer-term procurement planning and online and retail pharmacies leveraging centralized logistics to smooth episodic supply disruptions. Overall, tariffs have catalyzed longer-term supply chain optimization, with implications for pricing negotiations, procurement flexibility, and strategic partnership formation across the ecosystem.

In-depth segmentation intelligence articulating how indication, drug type, distribution channel, end-user, therapy line, and oral administration intersect to drive strategic choices

Segmentation analysis reveals distinct clinical and commercial dynamics when examining indications, drug types, distribution channels, end users, therapy lines, and routes of administration in an integrated manner. When considering indication breakdowns across colorectal cancer with both early-stage CRC and metastatic CRC, lung cancer characterized by NSCLC and SCLC subtypes, and melanoma with advanced and metastatic presentations, clinical pathway complexity varies substantially: metastatic settings emphasize systemic sequencing and combination strategies while early-stage contexts prioritize curative-intent considerations and adjuvant decision-making.

Drug-specific differentiation among dabrafenib, encorafenib, and vemurafenib manifests in clinical positioning, dosing schedules, and historical evidence bases; these characteristics inform lifecycle management and real-world utilization patterns. Distribution channel nuance between hospital pharmacy environments that include private and public facilities, online pharmacy capabilities, and retail pharmacy formats comprised of chain and independent operators affects patient access pathways and reimbursement interactions. End-user segmentation contrasts hospitals, which include general hospitals and specialty cancer centers, with specialist clinics that span hospital outpatient clinics and independent clinics, and this split influences prescribing concentration, clinical trial participation, and supportive care infrastructure. Therapy line segmentation into first-line and second-line use cases dictates enrollment strategies, payer negotiations, and diagnostic adoption, whereas the oral route of administration simplifies outpatient delivery but increases the importance of adherence programs and remote monitoring solutions. Together, these segmentation lenses provide a multidimensional framework to align clinical trial design, market access planning, and commercial operations with where and how patients actually receive BRAF-directed therapies.

Strategic regional perspective detailing how regulatory frameworks, payer dynamics, and diagnostic capacity vary across the Americas, Europe Middle East and Africa, and Asia-Pacific influencing access and adoption

Regional dynamics exert pronounced influence on regulatory pathways, clinical adoption, and commercial access across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory harmonization in certain jurisdictions and strong payer influence lead stakeholders to emphasize robust real-world evidence generation and health economics modeling to support formulary placement. Clinical trial networks and academic centers in this region often act as early adopters for label-expanding studies, which in turn accelerates diagnostic uptake and prescriber familiarity with BRAF-targeted regimens.

Europe, the Middle East & Africa present a heterogeneous mosaic where centralized regulatory processes coexist with diverse reimbursement frameworks, prompting manufacturers to develop differentiated access strategies that include managed entry agreements and region-specific evidence packages. In parts of this region, constrained healthcare budgets and variable diagnostic capacity require targeted investments in laboratory infrastructure and provider education. Asia-Pacific is characterized by rapid capacity building in molecular diagnostics, expanding clinical research activity, and strategic manufacturing hubs, which can benefit both supply security and localized clinical data generation. Taken together, these regional profiles inform prioritization of regulatory filings, commercialization sequencing, and partnerships that optimize patient access while respecting local payer and provider nuances.

Corporate strategic read on how portfolio strategies, diagnostic collaborations, supply chain choices, and partnership architectures determine durable commercial advantage in BRAF therapies

Competitive dynamics among companies engaged in BRAF inhibitor development and commercialization are defined by portfolio breadth, diagnostic partnerships, and supply chain integration. Organizations with diversified oncology portfolios can leverage cross-portfolio synergies to support market access, while specialty firms often focus on label expansion, combination studies, and targeted engagement with key opinion leaders to drive adoption in niche indications. Partnerships between therapeutic developers and diagnostic providers have become a cornerstone of successful commercialization, ensuring timely mutation detection and aligning reimbursement dossiers with clinical decision-making protocols.

Strategic maneuvers such as licensing deals, co-development agreements, and selective acquisitions of complementary assets have become common as companies seek to enhance evidence generation and secure market positions. Manufacturing strategy, including the use of contract development and manufacturing organizations versus in-house API production, influences cost structures and supply resilience. Companies that prioritize patient support, adherence programs, and digital health initiatives improve long-term treatment retention and commercial outcomes. Collectively, these company-level insights highlight the importance of an integrated approach that couples clinical differentiation with pragmatic operational execution to sustain competitive advantage.

Action-oriented strategic recommendations for manufacturers, payers, and providers to align diagnostics, supply resilience, and commercial execution for sustained market success

Industry leaders should prioritize an integrated strategy that aligns clinical development with diagnostics, supply chain resilience, and tailored commercial access pathways to maximize the value of BRAF-targeted assets. Investment in durable diagnostic partnerships and point-of-care testing pathways will accelerate appropriate patient identification and strengthen payer conversations, while concurrent real-world evidence programs should be designed to address comparative effectiveness and long-term safety questions that matter to clinicians and reimbursement bodies. Operationally, firms must stress test supply chains for tariff and trade shocks, consider dual-sourcing for critical APIs, and evaluate nearshoring or vertical integration where cost-effective to protect continuity of supply.

Commercial teams should expand patient support and adherence programs to reflect the oral route of administration and to enable decentralized care models that reduce barriers to therapy initiation and continuation. Engagement with hospital formulary committees, specialty clinics, and retail pharmacy networks must be tailored by segment to reflect prescribing concentration and procurement dynamics. Finally, cross-functional alignment between clinical, regulatory, government affairs, and commercial teams will accelerate market access wins and facilitate agile responses to policy changes, reimbursement shifts, and emerging clinical evidence.

Transparent description of the mixed methods research approach combining expert interviews, regulatory validation, and literature triangulation to ensure credible and actionable insights

The research methodology underpinning this analysis combined primary qualitative engagement with oncology clinicians, pharmacy directors, and market access specialists alongside systematic secondary literature review and public regulatory records. Key opinion leader interviews were conducted to validate clinical adoption patterns, real-world treatment sequencing, and the practical implications of diagnostic workflows. Supply chain and distribution channel insights were obtained through discussions with hospital procurement leaders, specialty pharmacy operators, and independent clinic administrators to capture differences in contracting and inventory practices.

Findings were triangulated across sources and cross-validated against regulatory approvals, clinical trial registries, and published peer-reviewed evidence to ensure accuracy and relevance. Where discrepancies emerged, follow-up interviews and document-level verification were used to reconcile interpretations. The methodology emphasizes transparency in assumptions, clear articulation of data provenance, and acknowledgment of limitations such as variable regional reporting practices and evolving clinical trial outcomes that may change the evidence base over time. This approach yields a defensible and actionable evidence set suitable for strategic planning and commercial decision-making.

Concise synthesis highlighting the imperative to integrate clinical evidence, diagnostic alignment, and supply chain resilience to drive patient access and commercial performance

The cumulative analysis underscores that success in the BRAF inhibitor space is contingent upon a holistic integration of clinical differentiation, diagnostic alignment, and operational resilience. Clinical advancements and combination strategies require synchronized evidence generation and pragmatic commercialization plans that reflect the realities of outpatient oral therapy delivery. Supply chain and trade policy dynamics, including tariff-driven cost pressures, have heightened the importance of diversified sourcing and proactive procurement strategies to maintain continuity and control costs in provider settings.

Regional heterogeneity in regulatory and reimbursement environments necessitates tailored market entry and access approaches, while segmentation insights reveal where investment in diagnostics, patient support, and provider education will yield the greatest return in terms of uptake and persistence. Collectively, these conclusions point to a strategic imperative for manufacturers and partners to adopt adaptive, evidence-driven approaches that bridge clinical innovation with real-world delivery, ensuring patients can access appropriate BRAF-targeted therapies across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. BRAF Inhibitors Market, by Indication

  • 8.1. Colorectal Cancer
    • 8.1.1. Early Stage Crc
    • 8.1.2. Mcrc
  • 8.2. Lung Cancer
    • 8.2.1. Nsclc
    • 8.2.2. Sclc
  • 8.3. Melanoma
    • 8.3.1. Advanced Melanoma
    • 8.3.2. Metastatic Melanoma

9. BRAF Inhibitors Market, by Drug Type

  • 9.1. Dabrafenib
  • 9.2. Encorafenib
  • 9.3. Vemurafenib

10. BRAF Inhibitors Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Second Line

11. BRAF Inhibitors Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
    • 11.1.1. Private Hospital Pharmacy
    • 11.1.2. Public Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. BRAF Inhibitors Market, by End User

  • 12.1. Hospitals
    • 12.1.1. General Hospitals
    • 12.1.2. Specialty Cancer Centers
  • 12.2. Specialist Clinics
    • 12.2.1. Hospital Outpatient Clinics
    • 12.2.2. Independent Clinics

13. BRAF Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. BRAF Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. BRAF Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States BRAF Inhibitors Market

17. China BRAF Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Asana BioSciences LLC
  • 18.6. AstraZeneca
  • 18.7. Bayer AG
  • 18.8. BeiGene Ltd.
  • 18.9. Black Diamond Therapeutics Inc
  • 18.10. Bristol-Myers Squibb
  • 18.11. C4 Therapeutics
  • 18.12. F. Hoffmann-La Roche Ltd.
  • 18.13. Fore Biotherapeutics Inc
  • 18.14. Jazz Pharmaceuticals Plc
  • 18.15. Kinnate Biopharma Inc.
  • 18.16. Nerviano Medical Sciences S.r.l
  • 18.17. Novartis International AG
  • 18.18. Ono Pharmaceutical Co. Ltd.
  • 18.19. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS BRAF INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. G7 BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA BRAF INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2032 (USD MILLION)